# Propensity score matching

Among 101,243 patients at a cancer center, those with brown fat had fewer cardiovascular and psychiatric diagnoses; machine learning quantified brown fat activity in about 8,700 people, showing higher activity, especially in the axillary depot, tracked with lower odds of type 2 diabetes and coronary disease, and led to losartan as an activator in mice.

Among 101,243 patients at a cancer center, those with brown fat had fewer cardiovascular and psychiatric diagnoses; machine learning quantified brown fat activity in about 8,700 people, showing higher activity, especially in the axillary depot, tracked with lower odds of type 2 diabetes and coronary disease, and led to losartan as an activator in mice.

This retrospective study analyzed patients undergoing inguinal hernia repair between January 2021 and December 2024, using 1:1 nearest-neighbor propensity score matching to compare 280 patients who received perioperative celecoxib plus dexamethasone with 280 who did not, and found an overall one-year recurrence rate of 5.0% (28/560), an independent association between treatment and lower recurrence risk (HR=0.45, 95% CI: 0.24-0.84, P=0.011), a significant interaction with BMI (P=0.032) with a stronger association in obese patients (HR=0.32, 95% CI: 0.14-0.71) than non-obese patients (HR=0.68, 95% CI: 0.31-1.52), along with lower acute pain scores, less postoperative nausea and vomiting (P<0.001), lower chronic pain risk (aOR=0.42, 95% CI: 0.23-0.78, P=0.

This retrospective study analyzed patients undergoing inguinal hernia repair between January 2021 and December 2024, using 1:1 nearest-neighbor propensity score matching to compare 280 patients who received perioperative celecoxib plus dexamethasone with 280 who did not, and found an overall one-year recurrence rate of 5.0% (28/560), an independent association between treatment and lower recurrence risk (HR=0.45, 95% CI: 0.24-0.84, P=0.011), a significant interaction with BMI (P=0.032) with a stronger association in obese patients (HR=0.32, 95% CI: 0.14-0.71) than non-obese patients (HR=0.68, 95% CI: 0.31-1.52), along with lower acute pain scores, less postoperative nausea and vomiting (P<0.001), lower chronic pain risk (aOR=0.42, 95% CI: 0.23-0.78, P=0.